TY - JOUR
T1 - Pre-diagnosis body mass index, physical activity and ovarian cancer mortality
AU - Zamorano, Abigail S.
AU - Hagemann, Andrea R.
AU - Morrison, Leavitt
AU - Lee, Jung Ae
AU - Liao, Linda M.
AU - Brinton, Louise A.
AU - Park, Yikyung
AU - Toriola, Adetunji T.
N1 - Funding Information:
The NIH-AARP research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute . We are indebted to the participants in the NIH-AARP Diet and Health Study for their outstanding cooperation; http://dietandhealth.cancer.gov/acknowledgement.html .
Funding Information:
The NIH-AARP research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute. We are indebted to the participants in the NIH-AARP Diet and Health Study for their outstanding cooperation; http://dietandhealth.cancer.gov/acknowledgement.html. Adetunji T. Toriola is supported by the Siteman Cancer Center, Barnes-Jewish Hospital Foundation. Abigail S. Zamorano is supported by the T32 NIH Cancer Prevention and Control Training Grant (Grant No. 5T32CA190194-04). Funding sources have no roles in study design and interpretation. Abigail Zamorano: Data interpretation, Drafting of manuscript, Critical review of manuscript, Final approval of manuscript. Andrea Hagemann: Critical review of manuscript, Final approval of manuscript. Leavitt Morrison: Data analysis, Final approval of manuscript. Jung Ae Lee: Data analysis, Final approval of manuscript. Linda Liao: Conception and design of the project, Critical review of manuscript, Final approval of manuscript. Louise Brinton: Conception and design of the project, Critical review of manuscript, Final approval of manuscript. Yikyung Park: Conception and design of the project, Critical review of manuscript, Final approval of manuscript. Adetunji Toriola: Conception and design of the project, Data interpretation, Drafting of manuscript, Critical review of manuscript, Final approval of manuscript.
Funding Information:
Adetunji T. Toriola is supported by the Siteman Cancer Center, Barnes-Jewish Hospital Foundation . Abigail S. Zamorano is supported by the T32 NIH Cancer Prevention and Control Training Grant (Grant No. 5T32CA190194-04 ). Funding sources have no roles in study design and interpretation.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Background: Ovarian cancer is the deadliest gynecologic malignancy, yet the effects on survival of modifiable pre-diagnosis lifestyle factors, such as obesity and physical activity, remain largely unexplored. Our objective was to evaluate the effect of pre-diagnosis BMI and physical activity on ovarian cancer mortality using prospectively collected data. Methods: Data on women who developed ovarian cancer after enrollment into the NIH-AARP Diet and Health Study were analyzed. Cancer incidence was ascertained through linkage state cancer registries and consisted of 741 cases of epithelial ovarian cancer. Results: Higher pre-diagnosis BMI was associated with increased overall and ovarian cancer-specific mortality. Comparing women with BMI 25–29.9, 30–34.9 and ≥ 35 to normal weight women, the HRs of overall mortality were 1.18 (95%CI 0.96–1.45), 1.05 (0.82–1.36) and 1.59 (1.14–2.18, p-trend = 0.02). The findings were similar for ovarian cancer-specific mortality comparing women with BMI ≥ 35 to normal weight women (BMI <25) with a HR of 1.47 (95%CI 1.03–2.09, p-trend 0.08). Pre-diagnosis physical activity was not associated with mortality, with HRs for overall mortality of 1.06 (95%CI 0.79–1.43), 0.94 (0.72–1.23), 0.98 (0.76–1.25), and 0.98 (0.75–1.28, p-trend = 0.91), comparing women who engaged in vigorous physical activity 1–3 times/month, 1–2 times/week, 3–4 times/week and 5 times/week, respectively, with those who never/rarely engaged in such activity. Conclusions: Women who were obese before developing ovarian cancer had increased mortality than those who were normal weight, but physical activity before diagnosis was not associated with mortality in this study population. These results suggest that maintaining a healthy weight is a powerful preventative tool.
AB - Background: Ovarian cancer is the deadliest gynecologic malignancy, yet the effects on survival of modifiable pre-diagnosis lifestyle factors, such as obesity and physical activity, remain largely unexplored. Our objective was to evaluate the effect of pre-diagnosis BMI and physical activity on ovarian cancer mortality using prospectively collected data. Methods: Data on women who developed ovarian cancer after enrollment into the NIH-AARP Diet and Health Study were analyzed. Cancer incidence was ascertained through linkage state cancer registries and consisted of 741 cases of epithelial ovarian cancer. Results: Higher pre-diagnosis BMI was associated with increased overall and ovarian cancer-specific mortality. Comparing women with BMI 25–29.9, 30–34.9 and ≥ 35 to normal weight women, the HRs of overall mortality were 1.18 (95%CI 0.96–1.45), 1.05 (0.82–1.36) and 1.59 (1.14–2.18, p-trend = 0.02). The findings were similar for ovarian cancer-specific mortality comparing women with BMI ≥ 35 to normal weight women (BMI <25) with a HR of 1.47 (95%CI 1.03–2.09, p-trend 0.08). Pre-diagnosis physical activity was not associated with mortality, with HRs for overall mortality of 1.06 (95%CI 0.79–1.43), 0.94 (0.72–1.23), 0.98 (0.76–1.25), and 0.98 (0.75–1.28, p-trend = 0.91), comparing women who engaged in vigorous physical activity 1–3 times/month, 1–2 times/week, 3–4 times/week and 5 times/week, respectively, with those who never/rarely engaged in such activity. Conclusions: Women who were obese before developing ovarian cancer had increased mortality than those who were normal weight, but physical activity before diagnosis was not associated with mortality in this study population. These results suggest that maintaining a healthy weight is a powerful preventative tool.
KW - Mortality
KW - Obesity
KW - Ovarian cancer
KW - Physical activity
KW - Pre-diagnosis
KW - Prospective
UR - http://www.scopus.com/inward/record.url?scp=85072904158&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2019.07.025
DO - 10.1016/j.ygyno.2019.07.025
M3 - Article
C2 - 31383570
AN - SCOPUS:85072904158
SN - 0090-8258
VL - 155
SP - 105
EP - 111
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -